_PRIVATE_LIMITED.webp)
Genomix Healthcare (India) Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 17-12-2024
- Paid Up Capital ₹ 0.10 M
as on 17-12-2024
- Company Age 14 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 5.65%
(FY 2017)
- Profit 89.08%
(FY 2017)
- Ebitda 139.55%
(FY 2017)
- Net Worth -15.78%
(FY 2017)
- Total Assets -93.01%
(FY 2017)
About Genomix Healthcare (India)
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rathnagiri Polavarapu and Ojasvi Polavarapu serve as directors at the Company.
- CIN/LLPIN
U24233TG2010PTC070254
- Company No.
070254
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Sep 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Genomix Healthcare (India)?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rathnagiri Polavarapu  | Director | 01-Sep-2010 | Current |
Ojasvi Polavarapu  | Director | 01-Sep-2010 | Current |
Financial Performance and Corporate Structure Insights of Genomix Healthcare (India).
Genomix Healthcare (India) Private Limited, for the financial year ended 2017, experienced modest growth in revenue, with a 5.65% increase. The company also saw a substantial improvement in profitability, with a 89.08% increase in profit. The company's net worth observed a substantial decline by a decrease of 15.78%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Genomix Healthcare (India)?
In 2017, Genomix Healthcare (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Genomix Molecular Diagnostics Private LimitedActive 17 years 11 monthsRathnagiri Polavarapu is a mutual person
Genomix Carl Private LimitedActive 9 years 24 daysRathnagiri Polavarapu and Ojasvi Polavarapu are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Genomix Healthcare (India)?
Unlock and access historical data on people associated with Genomix Healthcare (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Genomix Healthcare (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Genomix Healthcare (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
